Supplement

You have full text access to this OnlineOpen article

Effective but cost-prohibitive drugs in breast cancer treatment†‡

A clinician's perspective

  1. Jose Bines MD1,§,¶,*,
  2. Alexandru Eniu MD2

Article first published online: 3 OCT 2008

DOI: 10.1002/cncr.23837

Issue

Cancer

Cancer

Supplement: Guidelines for International Breast Health and Cancer Control–Implementation

Volume 113, Issue Supplement 8, pages 2353–2358, 15 October 2008

Additional Information

How to Cite

Bines, J. and Eniu, A. (2008), Effective but cost-prohibitive drugs in breast cancer treatment. Cancer, 113: 2353–2358. doi: 10.1002/cncr.23837

Author Information

  1. 1

    Instituto Nacional de Cancer, Rio de Janeiro, Brazil

  2. 2

    Department of Breast Tumors, Cancer Institute “Ion Chiricuta,” Cluj-Napoca, Romania

  1. §

    Dr. Bines has received honoraria from Astra-Zeneca and has acted as either a consultant or in an advisory role for Bristol Myers-Squibb and Astra-Zeneca.

  2. Fax: (011) 55-21-2577-6941

*Instituto Nacional de Cancer-Brasil, Rua Visconde de Santa Isabel 274, Rio de Janeiro, Brasil

  1. †

    The views expressed in this article are the results of independent work and do not represent the views of the authors' institutions.

  2. ‡

    Complete financial disclosures are presented at the end of this article.

Publication History

  1. Issue published online: 3 OCT 2008
  2. Article first published online: 3 OCT 2008
  3. Manuscript Accepted: 24 JUN 2008
  4. Manuscript Received: 10 JUN 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (161K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    A.J.S. Carvalho, T. Ishikawa, C.M.C.P. Gouvêa, Aqueous extract of Plinia edulis leaves: Antioxidant activity and cytotoxicity to human breast cancer MCF-7 cell line, South African Journal of Botany, 2012, 81, 1

    CrossRef

  2. 2
    Brittany L Lee, Pedro ER Liedke, Carlos H Barrios, Sergio D Simon, Dianne M Finkelstein, Paul E Goss, Breast cancer in Brazil: present status and future goals, The Lancet Oncology, 2012, 13, 3, e95

    CrossRef

  3. 3
    Laura Vera-Ramirez, Pedro Sanchez-Rovira, M. Carmen Ramirez-Tortosa, Cesar L. Ramirez-Tortosa, Sergio Granados-Principal, Jose A. Lorente, Jose L. Quiles, Oxidative stress status in metastatic breast cancer patients receiving palliative chemotherapy and its impact on survival rates, Free Radical Research, 2012, 46, 1, 2

    CrossRef

  4. 4
    Laura Vera-Ramirez, Pedro Sanchez-Rovira, M. Carmen Ramirez-Tortosa, Cesar L. Ramirez-Tortosa, Sergio Granados-Principal, Monica Fernandez-Navarro, Jose A. Lorente, Jose L. Quiles, Does Chemotherapy-Induced Oxidative Stress Improve the Survival Rates of Breast Cancer Patients?, Antioxidants & Redox Signaling, 2011, 15, 4, 903

    CrossRef

  5. 5
    Luiz Henrique Lima Araújo, Marcos Veloso Moitinho, Ana Maria Fantini Silva, Cleudes Alice Sousa Gomes, Hélio Noronha Júnior, Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: a Brazilian experience, Medical Oncology, 2010, 28, S1, 2

    CrossRef

  6. 6
    Richard R. Love, Defining a global research agenda for breast cancer, Cancer, 2008, 113, S8
    Direct Link:
  7. 7
    Benjamin O. Anderson, Cheng-Har Yip, Robert A. Smith, Roman Shyyan, Stephen F. Sener, Alexandru Eniu, Robert W. Carlson, Edward Azavedo, Joe Harford, Guideline implementation for breast healthcare in low-income and middle-income countries, Cancer, 2008, 113, S8
    Direct Link:
View Full Article (HTML) Get PDF (161K)